Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
- 1 August 2001
- journal article
- controversies in-neurology
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 58 (8), 1299-1300
- https://doi.org/10.1001/archneur.58.8.1299
Abstract
THE NEUROLOGIST, like an Argonaut in his search for the Golden Fleece, has through the years been doggedly trying to achieve his lofty goal of optimally treating his or her patients with multiple sclerosis (MS). Progress has been made. A recombinant cytokine, interferon beta (administered as Betaseron or Avonex), has been widely used in the past decade and is the first recombinant protein extensively prescribed by neurologists. It is thus a "pioneer" therapy from which we all need to learn as much as possible before the next recombinant protein is available.Keywords
This publication has 3 references indexed in Scilit:
- Immunoregulation and blocking antibodies induced by interferon beta treatment in MSNeurology, 2000
- Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1bJournal of the Neurological Sciences, 1999
- Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodiesNeurology, 1999